dry age-related macular degeneration Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 24, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: dry age-related macular degeneration. It connects disease context, epidemiology, target mechanism, clinical competition, transactions, unmet need and market attractiveness for portfolio and partnering decisions.

Executive assessment

dry age-related macular degeneration receives a directional strategic score of 55/100, combining unmet need (67/100), competitive intensity (96/100, where higher means more competition) and market attractiveness (79/100). The score is a transparent prioritization aid, not a revenue forecast, clinical recommendation or investment conclusion.

Disease background and strategic definition

dry age-related macular degeneration is a clinically defined disorder requiring careful phenotype and severity segmentation before development decisions.

The reproducible entity is Patsnap disease ID 164ba9b819474bcd9c0f89bbf21a934c. Stable identifiers are important because rare and precision-defined diseases often carry historical labels, gene-defined subtypes and overlapping syndromic names.

A credible target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, treatment setting, acceptable safety and endpoint. A broad label may inflate theoretical market size while weakening biological signal, trial interpretability and recruitment feasibility. The first population should be narrow enough for coherent biology but large enough for execution.

The care pathway should be mapped from symptom recognition through referral, diagnostic testing, treatment initiation and longitudinal monitoring. Diagnostic delay, limited specialist centers and fragmented testing can constrain both trial enrollment and commercial access. These bottlenecks deserve explicit operational assumptions.

Epidemiology and disease burden

Epidemiology evidence 1: Global burden of vision impairment due to age-related macular degeneration, 1990–2021, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021

### Chart Data Transcription Report 1. Basic Chart Information * Chart Title: Age-standardised prevalence rate (A) and DALYs (B) per 100 000 of the population from age-related macular degeneration for both sexes by SDI, 2021 * Chart Type: Line Charts with Shaded Uncertainty Intervals * Contextual Summary: This chart illustrates the trends in age-standardised prevalence rates and disability-adjusted life-years (DALYs) per 100,000 population for age-related macular degeneration from 1990 to 2020, stratified by global and different Socio-demographic Index (SDI) levels. 2. Chart Structure and Elements * Axes/Headers: * Panel A: * X-Axis: Year (1990 to 2020) * Y-Axis: Prevalence rate (per 100 000 population) * Panel B: * X-Axis: Year (1990 to 2020) * Y-Axis: DALYs rate (per 100 000 population) * Legend/Groups: The charts present data for: * Global * Low SDI * Low-middle SDI * Middle SDI * High-middle SDI * High SDI The shaded regions around each line indicate the 95% uncertainty intervals. * Notes and Footnotes: Shaded regions indicate 95% uncertainty intervals. DALYs=disability-adjusted life-years. SDI=Socio-demographic Index. 3. Detailed Data Transcription This report describes the trends in age-standardised prevalence rates (Panel A) and DALYs rates (Panel B) per 100,000 population from 1990 to 2020, stratified by global and various SDI levels. Panel A: Age-standardised prevalence rate (per 100 000 population) * Global: The prevalence rate shows a slight decrease from approximately 105 per 100,000 in 1990 to around 95 per 100,000 in 2020. The 95% uncertainty interval (UI) gen

Review the epidemiology source

Epidemiology evidence 2: 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

• Among 1554 participants from 1997 to 2022 in the Religious Orders Study and the Rush Memory and Aging Project with autopsy data, there were no differences in the age-standardized prevalence of pathological AD diagnosis (P=0.76 across year of birth groups).36 However, there was a decrease in the prevalence of neurodegenerative pathologies related to atherosclerosis/arteriosclerosis (eg, mod­ erate to severe atherosclerosis was 54% among those born from 1905–1914, 37% for those born in 1915–1919, 30% for those born in 1920–1924, and 22% for those born in 1925–1930; P<0.001 across birth year categories, χ2 test). • According to an analysis of GBD Study data from 1990 to 2017, age-standardized incidence rates of AD/ADRD in the United States decreased from 97.2 per 100 000 to 85.2 per 100 000 (12.4% decrease [95% UI, 5.2%–19.2%]), and age- standardized prevalence decreased from 542.7 per 100 000 to 470.0 per 100 000 (13.4% decrease [95% UI, 5.1%–20.6%]); however, mortality rates increased from 35.0 per 100 000 to 38.5 per 100 000 (9.8% increase [95% UI, 7.3%–12.2%]), and DALY rates increased from 413.6 per 100 000 to 418.8 per 100 000 (1.2% increase [95% UI, 1.9% decrease–4.2% increase]).14 • Between 1990 and 2019, the GBD Study esti­ mated a significant increase globally in age- standardized mortality rates from dementia for males of 5.1% (95% CI, 0.4%–12.0%) and a non­ significant increase for females of 3.0% (95% CI, −2.6% to 11.0%).37 The global all-age mortality rate from dementia increased 100.1% (95% CI, 89.1%–117.5%).

Review the epidemiology source

Epidemiology evidence 3: Global, regional, and national burden of autoimmune disease in older adults (≥60 years) from 1990 to 2021: Results from the Global Burden of Disease Study 2021

Age-related patterns further contextualize disease burden. DALYs and mortality from RA and IBD rose steeply with advancing age, underscoring their heavy toll among the oldest-old. Although IBD inci­ dence declined with age, the disproportionate rise in mortality and DALYs suggests that older patients may experience more severe disease progression, complications, or limited access to advanced treatments. For RA and psoriasis, incidence and prevalence peaked around age 70 before declining, which may reflect survivor bias or lower diagnostic activity in advanced age. In contrast, T1DM showed steadily rising incidence and DALYs across older age groups, highlighting the ongoing clinical and public health challenge of managing long-standing meta­ bolic and ADs in aging populations.i Decomposition analyses further clarified the drivers of these pat­ terns. Population growth consistently fueled increases in incidence and DALYs for all five diseases, particularly magnifying the absolute burdens in South and East Asia. Aging also played a major role, especially in increasing the incidence and DALYs of RA and T1DM, while mitigating IBD and psoriasis. Improvements in epidemiologic surveillance and treatment contributed to declining mortality and DALYs for most dis­ eases, demonstrating the impact of stronger healthcare systems. These findings highlight how demographic and epidemiologic transitions interact to shape the evolving burden of ADs in older adults. Projections to 2035 indicate continued increases in the incidence and prevalence of RA, IBD, psoriasis, and to a lesser degree MS

Review the epidemiology source

Translate epidemiology into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence cannot be substituted for one another, and incompatible case definitions should not be pooled.

For dry age-related macular degeneration, quantify diagnostic yield, age and severity distribution, referral-center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges. Each parameter should have a source, access date and explanation of how it maps to the intended clinical population.

Population concentration can materially change strategy. A small but well-defined group managed in a limited number of centers may be operationally attractive, while a larger but poorly diagnosed population may require extensive testing and education. Epidemiology must therefore connect to the real patient journey.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: irreversible progression, incomplete control, treatment-limiting toxicity, weak durability, burdensome administration, delayed diagnosis or lack of options for a biomarker-defined subgroup. Disease severity alone does not prove that a new program can demonstrate clinically meaningful benefit.

A strong dry age-related macular degeneration thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Functional measures, patient-reported outcomes and resource use may complement biomarkers.

Development should proceed through evidence gates. Establish phenotype and natural history, demonstrate target engagement, observe a pharmacodynamic response, show an interpretable clinical signal and only then scale toward registrational development. Pre-agreed stop criteria protect capital and improve learning from negative results.

Target mechanism anchor: RPE65

Critical isomerohydrolase in the retinoid cycle involved in regeneration of 11-cis-retinal, the chromophore of rod and cone opsins. Catalyzes the cleavage and isomerization of all-trans-retinyl fatty acid esters to 11-cis-retinol which is further oxidized by 11-cis retinol dehydrogenase to 11-cis-retinal for use as visual chromophore (PubMed:16116091). Essential for the production of 11-cis retinal for both rod and cone photoreceptors (PubMed:17848510). Also capable of catalyzing the isomerization of lutein to meso-zeaxanthin an eye-specific carotenoid (PubMed:28874556). The soluble form binds vitamin A (all-trans-retinol), making it available for LRAT processing to all-trans-retinyl ester. The membrane form, palmitoylated by LRAT, binds all-trans-retinyl esters, making them available for IMH (isomerohydrolase) processing to all-cis-retinol. The soluble form is regenerated by transferring its palmitoyl groups onto 11-cis-retinol, a reaction catalyzed by LRAT (By similarity).

The mechanism anchor is RPE65. It is a pathway hypothesis, not a claim that every dry age-related macular degeneration patient is target-dependent. Translational work should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and a therapeutic window.

Critical experiments include orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit on-target and off-target safety testing. Human evidence should carry greater weight than model-only observations. Related clinical failures should be examined for exposure, population and endpoint lessons.

A go decision requires a complete chain: relevant target biology, achievable modulation at tolerated exposure, measurable pharmacodynamic change and a plausible bridge to clinical benefit. Missing links should trigger targeted experiments rather than narrative confidence.

Clinical development and competitive landscape

The focused query returned 167 registered studies. Recent sampled records include:

• NCT07770828 — Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD; Recruiting; Phase 3; sponsor Ocugen, Inc.; enrollment 237.
• NCT07700147 — Evaluation of an Electric Stimulator for Medical Use by Personal (LRTPM1) for Visual Function in Early to Intermediate Dry Age-Related Macular Degeneration; Not yet recruiting; Not Applicable; sponsor Nu Eyne Co. Ltd.; enrollment 40.
• NCT07680244 — (CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000; Recruiting; Not Applicable; sponsor Premier Eyecare of San Francisco, Moyes Eye Center, Retina-Vitreous Associates, Inc. (California); enrollment 400.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies from one asset can inflate activity. Normalize every record by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy should compare against the likely future standard at launch. Whitespace can arise from earlier treatment, genotype selection, improved durability, lower monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim must be visible in protocol design, not deferred to post hoc interpretation.

Recruitment risk is a core strategic variable. Site density, diagnostic testing, travel burden, competing protocols and screen-failure rates should inform country and center selection. Natural-history work can reduce uncertainty but cannot replace a controlled efficacy strategy when outcomes are variable.

Transaction activity and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering, broader transaction labels or asset-level indexing. Add target- and asset-based comparable searches before valuation.

Headline transaction value is rarely directly comparable. Separate upfront payments, milestones, royalties, options, bundled programs, platform rights and geographic scope. A useful comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual property, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that retires material risk.

Low direct deal activity can represent whitespace, but it can also signal difficult science or economics. Broader therapeutic-area transactions should be used only when their relevance is explicit. Avoid assuming that all rare-disease transactions share the same valuation logic.

Market attractiveness and access

Market attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, alternatives, monitoring burden and geographic reimbursement. Patient count is only one driver. Reliable identification and a meaningful effect may outweigh a small population; fragmented diagnosis can undermine a larger one.

The commercial model should use scenario ranges for diagnosed prevalence, eligible share, launch timing, competitive entries, net price, persistence and penetration. Every assumption should be traceable. Refresh the model when new epidemiology, trial or deal evidence becomes available.

Payer research should begin before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Evidence may need quality of life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The value proposition should connect clinical effect to stakeholder-relevant outcomes.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate RPE65 relevance in the selected phenotype.
• Translation risk: connect engagement to a biomarker and meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing and screen-failure assumptions.
• Commercial risk: test pricing, access and adoption with clinicians and payers.
• Data risk: treat zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are population confirmation, human mechanism validation, differentiated target product profile, early proof of mechanism and scale-up only after biological, clinical, operational and commercial signals converge.

Strategic recommendation

dry age-related macular degeneration merits continued milestone-based evaluation. The opportunity is strongest if a phenotype or biomarker identifies patients with coherent biology, if RPE65 modulation is measurable and if the proposed benefit remains differentiated against future care. Current evidence supports targeted diligence rather than unconditional investment.

The near-term business-development objective is a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard offers a common comparison language while preserving evidence gaps and uncertainty.

Methodology and source note

This report was assembled on August 24, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update.

Ranking weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio commitment.

Conclusion

The key question for dry age-related macular degeneration is whether a biologically grounded therapy can deliver material patient benefit in an identifiable population and remain differentiated through launch. The evidence assembled here supplies a structured starting point, while the explicit gaps define the next diligence plan.